Shih Ya-Chen Tina, Halpern Michael T
Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
CA Cancer J Clin. 2008 Jul-Aug;58(4):231-44. doi: 10.3322/ca.2008.0008.
While the past decade has seen the development of multiple new interventions to diagnose and treat cancer, as well as to improve the quality of life for cancer patients, many of these interventions have substantial costs. This has resulted in increased scrutiny of the costs of care for cancer, as well as the costs relative to the benefits for cancer treatments. It is important for oncologists and other members of the cancer community to consider and understand how economic evaluations of cancer interventions are performed and to be able to use and critique these evaluations. This review discusses the components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples. We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses.
在过去十年中，出现了多种用于诊断和治疗癌症以及改善癌症患者生活质量的新干预措施，但其中许多干预措施成本高昂。这导致对癌症护理成本以及癌症治疗成本效益比的审查日益严格。肿瘤学家和癌症领域的其他人员必须考虑并理解癌症干预措施的经济评估是如何进行的，并且能够运用和评判这些评估。本综述以癌症干预措施研究为例，讨论了卫生经济评估的组成部分、主要类型和分析问题。我们还强调了这些经济评估的局限性，并讨论了癌症领域人员为何应关注经济分析。
